Thorsten Graef
Multimeric Biotherapeutics (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Multiple Myeloma Research and Treatments, Histone Deacetylase Inhibitors Research, Protein Degradation and Inhibitors, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia(2015)917 cited
- → Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial(2013)465 cited
- → Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia(2018)345 cited
- → Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial(2016)233 cited
- → KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C(2009)232 cited
- → Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study(2013)227 cited
- → Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase(2007)152 cited
- → Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes(2009)124 cited
- → Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands(2009)116 cited
- → The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia(2015)109 cited